Replidyne in-licenses faropenem daloxate
US biopharmaceutical company Replidyne, which focuses on the discovery and development of new anti-infective drugs, has obtained exclusive rights to faropenem daloxate from Daiichi Suntory Pharma, of Japan.
US biopharmaceutical company Replidyne, which focuses on the discovery and development of new anti-infective drugs, has obtained exclusive rights to faropenem daloxate from Daiichi Suntory Pharma, of Japan.
Replidyne will complete the clinical development of faropenem daloxate for use in community-acquired infections, and also intends to pursue a pediatric formulation for common bacterial infections.
Faropenem daloxate is a late stage clinical compound for the treatment of bacterial infections. It is an orally administered penem that has excellent in vitro activity against both Gram-positive and Gram-negative organisms, including common respiratory tract pathogens and strains showing resistance to other beta-lactam antibiotics.
'Replidyne has been aggressive in its pursuit of novel antibacterial programmes to address the growing problem of bacterial resistance to conventional antibiotics,' said Kenneth J. Collins, president and ceo of Replidyne. 'With faropenem daloxate, we are pleased to have acquired a first-in-class, late stage agent that addresses some of the largest antibiotic markets.'
'We are bringing to market in the US the first oral penem antibiotic that is intrinsically resistant to beta-lactamase degradation,' added Dr Nebojsa Janjic, senior vice president, research and development of Replidyne. 'This antibiotic represents an important treatment option in the face of increasing bacterial resistance.'
Replidyne has acquired exclusive rights to the compound for the US and Canada and an exclusive option to the rest of the world, except Japan. The company also has rights to the preclinical and clinical data generated to date. It has also entered into a supply arrangement with the drug substance manufacturer. Financial terms of the agreements were not disclosed.
Bayer Healthcare previously licensed faropenem daloxate and conducted a number of Phase III clinical studies. Faropenem daloxate was tested in more than 4000 patients with a favourable safety profile and encouraging efficacy results in several indications.